ArticleHepatobiliary surgery and nutrition2023

Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved.

Masato Yoneda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.